Atossa Therapeutics Inc (ATOS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -25,504 | -19,157 | -11,927 | -5,878 | -30,094 |
| Depreciation Amortization | 17 | 13 | 9 | 5 | 23 |
| Accounts payable and accrued liabilities | -127 | 755 | 250 | 424 | -2,159 |
| Other Working Capital | 448 | 1,934 | 1,916 | 756 | 1,519 |
| Other Operating Activity | 4,136 | 2,476 | 523 | -5 | 9,770 |
| Operating Cash Flow | $-21,030 | $-13,979 | $-9,229 | $-4,698 | $-20,941 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -19 | -19 | -9 | -6 | -14 |
| Investing Cash Flow | $-19 | $-19 | $-9 | $-6 | $-14 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 3,673 | 304 | 304 | 204 | N/A |
| Common Stock Repurchased | N/A | N/A | N/A | N/A | -1,475 |
| Financing Cash Flow | $3,673 | $304 | $304 | $204 | $-1,475 |
| Beginning Cash Position | 88,570 | 88,570 | 88,570 | 88,570 | 111,000 |
| End Cash Position | 71,194 | 74,876 | 79,636 | 84,070 | 88,570 |
| Net Cash Flow | $-17,376 | $-13,694 | $-8,934 | $-4,500 | $-22,430 |
| Free Cash Flow | |||||
| Operating Cash Flow | -21,030 | -13,979 | -9,229 | -4,698 | -20,941 |
| Capital Expenditure | -19 | -19 | -9 | -6 | -14 |
| Free Cash Flow | -21,049 | -13,998 | -9,238 | -4,704 | -20,955 |